US Stock Market Closed

Dashboard

SELLAS Life Sciences Group, Inc. (SLS)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

SELLAS Life Sciences Group, Inc. engages in the development and commercialization of immunotherapeutics for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

CEO

Angelos M. Stergiou

Employees

5

Industry

Oncology Biopharmaceuticals

Sector

Healthcare

Headquarters

New York

Exchange

NASDAQ

Summary Stats

Market Cap

68.6M

Revenue

1M

Net Income

-38.8M

EPS

-$2.29

Price-to-Earnings

-1.46

Price-to-Book

3.6

Debt-to-Equity

0.69

News

Analyst Ratings

Price targets projected by 1 analyst

High

$8.00

Average

$8.00

Low

$8.00

Ratings calculated by 0 analysts

Buy

0

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.05

Actual

-$0.34 +12.8%

Consensus

-0.39

Report Date

Year Ago

-0.45

Year Ago Change %

Up 24%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites